Drug Profile
NT 1 - Nanotargeting
Alternative Names: Aurocis; NT-1 - NanotargetingLatest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Nanotargeting
- Developer Ferrer; Nanotargeting
- Class Antineoplastics; Platinum complexes
- Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Cancer in Spain (Parenteral)
- 18 Jul 2016 Preclinical trials in Cancer in Spain (Parenteral)